Physician profile

James E Mckiernan

Neurology (Psychiatry & Neurology) · Louisville, KY

NPI 1336126515

$2,479.13

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sunovion Pharmaceuticals INC. $818.75 2019-2020
Ucb, INC. $395.61 2019-2020
Amgen INC. $221.76 2019-2021
Allergan, INC. $154.07 2019
Novartis Pharmaceuticals Corporation $144.04 2019
Akcea Therapeutics, INC. $121.10 2019
Eisai INC. $86.47 2019
Alexion Pharmaceuticals, INC. $72.96 2019
Acorda Therapeutics, INC $58.38 2019-2020
Promius Pharma LLC $57.81 2019
Aprecia Pharmaceuticals, LLC $57.59 2019-2020
Supernus Pharmaceuticals, INC. $41.61 2019-2020
Grifols USA, LLC $40.63 2019
Teva Pharmaceuticals USA, INC. $36.20 2019
Upsher-Smith Laboratories LLC $34.26 2019-2020
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $31.63 2019-2020
Acadia Pharmaceuticals INC $28.95 2019
Janssen Pharmaceuticals, INC $25.50 2019
Zyla Life Sciences, INC. $13.73 2020
Alnylam Pharmaceuticals INC. $13.68 2019
Avanir Pharmaceuticals, INC. $12.66 2019
Currax Pharmaceuticals LLC $11.74 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James E Mckiernan

$2,479.13

in general payments reported 2019-2025

Years
2019-2021
Top company
Sunovion Pharmaceuticals INC.

https://glasscript.com/doctor/332923/james-e-mckiernan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.